Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a new pill tame ulcerative colitis? a First-in-Human trial aims to find out

NCT ID NCT07749768

Not yet recruiting Disease control Sponsor: Ono Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This early-stage trial evaluates an investigational oral drug called ONO-6414 in healthy adults and in people with active ulcerative colitis. The main goals are to assess the drug's safety, tolerability, and how the body processes it. The study includes single and multiple doses, with a food-effect arm to see if eating changes drug levels. It is a first step to determine if ONO-6414 is safe enough for further testing as a potential treatment for ulcerative colitis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ONO-6414, an oral investigational drug
What this could lead to
If successful, this could lead to a new oral treatment option for ulcerative colitis, potentially helping to control the disease and reduce symptoms.
What could go wrong
This is an early-phase trial focused on safety and dosing, not effectiveness. The drug may not prove beneficial or could cause side effects, and results in healthy volunteers may not predict effects in patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ULCERATIVE COLITIS (UC)

Contacts and locations

Locations

  • Syneos Health Miami

    Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.